Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

Cancer cell - 1 May 2004

Dancey Janet E

Abstract excerpt

Studies have shown that epidermal growth factor receptor (EGFR) signaling is important to normal development and neoplastic transformation, and that EGFR inhibition reduces cancer cell proliferation. The promising response rates of the EGFR inhibitor gefitinib in patients with chemotherapy-refractory non-small cell lung cancer (NSCLC) led to its approval for clinical use. However, there was little understanding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Quinazolines

Source

Identifiers

PMID: 15144948
DOI: 10.1016/s1535-6108(04)00122-9

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.PMID 15144948Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Semantic proximity Read ↗

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Looking back on the history of epidermal growth factor receptor mutations in lung cancer.Semantic proximity Read ↗

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.Semantic proximity Read ↗

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.